DermBiont, Inc.
14
3
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
21.4%
3 terminated/withdrawn out of 14 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
100%
3 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor
Role: lead
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Role: lead
Randomized Study Using SM-030 Gel for Adults With Melasma
Role: lead
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
Role: lead
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
Role: lead
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)
Role: lead
Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel
Role: lead
Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos
Role: lead
Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis
Role: lead
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
Role: lead
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
Role: lead
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
Role: lead
A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis
Role: lead
Oral Health, Microbial Burden and COVID-19
Role: collaborator
All 14 trials loaded